CD274 and hepatocellular carcinoma: Zhu et al. retrospectively analyzed the gut microbiome, mycobiome (fungal community), and metabolome (metabolic products) of 80 HCC patients treated with ICIs (PD-1/PD-L1 inhibitors, with or without targeted therapy) [81].